Ankyra Therapeutics
PrivateLast Round
Series B
Nov 12, 2021
Total Funding Raised
$50M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ankyra Therapeutics is a biotechnology company that develops anchored-drug conjugates to enhance the safety and effectiveness of cytokine immunotherapies for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ankyra Therapeutics Comparables
Compare Ankyra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Xilio Therapeutics | 83% | |
| Bright Peak Therapeutics | 79% | |
| Synthekine | 79% | |
Ankyra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 12, 2021 | ||||
| Series A | May 4, 2020 |
Key People
Founding team and executive leadership
Ankyra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series B |
| Fidelity Management & Research Company | Series B |
| Borealis Ventures | Series B |
| Polaris Partners | Series B, Series A |
| Sands Capital | Series B |
| Spring Mountain Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 41% MoM.
- Apr 16, 2026
Clinical presentations on novel IL-12 immunotherapy at AACR 2026.
Ankyra Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ankyra Therapeutics's valuation, stock price, and market status.